Shares of GSK plc (LON:GSK – Get Free Report) have received an average recommendation of “Moderate Buy” from the seven analysts that are covering the company, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and five have issued a buy recommendation on the company. The average 12 month price target among analysts that have issued a report on the stock in the last year is GBX 1,805.71 ($23.85).
Several brokerages have issued reports on GSK. Deutsche Bank Aktiengesellschaft reissued a “buy” rating and issued a GBX 1,850 ($24.44) price target on shares of GSK in a report on Tuesday, September 3rd. Shore Capital reissued a “buy” rating on shares of GSK in a research report on Wednesday, August 28th. JPMorgan Chase & Co. reaffirmed an “underweight” rating on shares of GSK in a report on Monday, July 29th. Citigroup dropped their target price on GSK from GBX 2,120 ($28.01) to GBX 1,900 ($25.10) and set a “buy” rating for the company in a report on Friday, July 5th. Finally, Jefferies Financial Group reaffirmed a “buy” rating and issued a GBX 2,100 ($27.74) price target on shares of GSK in a research note on Thursday, June 27th.
Insider Transactions at GSK
GSK Stock Performance
GSK opened at GBX 1,600 ($21.14) on Wednesday. The stock has a market cap of £65.28 billion, a PE ratio of 1,424.34, a P/E/G ratio of 1.34 and a beta of 0.31. GSK has a 1 year low of GBX 1,371.40 ($18.12) and a 1 year high of GBX 1,823.50 ($24.09). The stock’s 50 day simple moving average is GBX 1,578.96 and its 200-day simple moving average is GBX 1,634.21. The company has a current ratio of 0.82, a quick ratio of 0.73 and a debt-to-equity ratio of 123.04.
GSK Announces Dividend
The firm also recently disclosed a dividend, which will be paid on Thursday, October 10th. Shareholders of record on Thursday, August 15th will be paid a GBX 15 ($0.20) dividend. This represents a yield of 0.97%. The ex-dividend date is Thursday, August 15th. GSK’s dividend payout ratio is currently 5,309.73%.
About GSK
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.
Featured Stories
- Five stocks we like better than GSK
- How Investors Can Find the Best Cheap Dividend Stocks
- Galmed Pharmaceuticals Surges 400%: What’s Behind the Explosion?
- Investing in the High PE Growth Stocks
- Gold Hits New All-Time Highs: 3 Stocks to Ride the Surge
- Biggest Stock Losers – Today’s Biggest Percentage Decliners
- Intel: Why It’s Time to Reconsider This Beaten-Down Chipmaker
Receive News & Ratings for GSK Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GSK and related companies with MarketBeat.com's FREE daily email newsletter.